
Harvie Says Use the Data!
When treating patients with opioid use disorder, treatment retention is everything. When patients leave treatment, their risk of death increases sharply.
Multiple studies show that two medications – buprenorphine and methadone – reduce the risk of overdose death. Most studies have found a reduction of at least two-fold in overdose death rates, though some found even higher reductions. [1, 2, 3]
For any other disease, if a medication was proven to reduce the risk of death (of death, mind you, not just risk of disease complications), it would be malpractice not to prescribe the medication immediately for patients with the disease.
But for opioid use disorder, abstinence-based treatment providers neglect to use these life-saving medications for thousands of patients every day. Or they recommend extended-release naltrexone, marketed under its brand name Vivitrol, instead of buprenorphine or methadone. Though Vivitrol is FDA-approved to treat opioid use disorder, studies have not shown this medication reduces overdose deaths. In fact, there’s now some questions about uncounted overdose deaths of patients given Vivitrol in one of the big studies, the XBOT study. (https://www.scientificamerican.com/article/vivitrol-used-to-fight-opioid-misuse-has-a-major-overdose-problem/ )
But I digress, and that could be a blog for a whole other day. Back to treatment retention.
Researchers have been looking for factors that will retain patients in treatment with buprenorphine and methadone, once they are on these medications. A recent metanalysis found that contingency management didn’t help retention, and neither did integration of psychiatric and medical services. Interestingly, extended-release formulations of buprenorphine didn’t show longer treatment retention than daily dosing of medication. [4]
In a recent study in the Journal of the American Medical Association, by Noysk et al., methadone was associated with longer treatment retention than buprenorphine. [5]
This was a big study, involving over thirty thousand patients. It was done in British Columbia, Canada, from 2010 through 2020, and involved patients starting medication for opioid use disorder. Patients were excluded if they were younger than 18, pregnant, or incarcerated. Around 40% started buprenorphine. Males accounted for 66% of these patients, and the median age was 33 years old.
The study authors found that patients who started buprenorphine/naloxone were significantly more likely to discontinue treatment compared to patients who started methadone. For the buprenorphine/naloxone patients, 88% had discontinued at 24 months, compared to 81.5% of patients who started methadone.
That translates into a 37 to 41 percent reduction in treatment discontinuation for methadone patients compared to buprenorphine patients.
There was no difference in mortality in the two groups of patients during treatment, however.
Importantly, the data collected during the study covered the years when fentanyl entered the drug supply of British Columbia. By 2016, fentanyl became the primary drug seen in opioid overdoses there.
But there are other reasons why this study may not be comparable in the U.S. For example, our U.S. system of specialized opioid treatment programs is different than treatment in Canada. While in the U.S., only treatment with buprenorphine products can be delivered in an office-based setting, Canada allow both methadone and buprenorphine to be provided in office settings. It seems probable that better retention would be seen in office-based settings.
The point of the study was that treatment retention was lower with buprenorphine compared to methadone. We’ve seen similar results in other studies.
Why is this data a big deal, you may ask. After all, U.S. guidelines don’t endorse buprenorphine over methadone. But some Canadian guidelines do. They say that buprenorphine/naloxone should be a first line agent, because it is safer than methadone. This study calls these guidelines into question.
Even though our U.S. guidelines don’t officially say buprenorphine is better than methadone, I see a bias against methadone even in Addiction Medicine circles. I’ve gone to state conferences where the speakers talk of the importance of starting patients on medication, and they talk for an hour about buprenorphine without once mentioning methadone.
I get it. Buprenorphine is much safer. It’s hard to inadvertently overdose a patient with buprenorphine.
But particularly in this time of fentanyl, we must consider the benefits of methadone. Methadone does not cause precipitated withdrawal in patients using fentanyl, which is a big advantage over buprenorphine. Sometimes we don’t get a second chance with these patients, if we start buprenorphine too soon and cause precipitated withdrawal. These days, we must consider either low-dose or high-dose induction strategies to start patients on buprenorphine.
Or we can avoid the issue altogether and start methadone.
To be fair, both methadone and buprenorphine show better retention in treatment with higher doses. For too long, treatment programs were too stingy with dosing for both, resulting in lower treatment retention.
When I first started working at an OTP in 2001, some physicians claimed that no patient needed more than 70mg. This was, literally, dead wrong. Studies showed doses of 80 to 120mg worked better and kept patients from relapsing and leaving treatment. Now, in these days of fentanyl as the main opioid of use, we often must use much higher doses of methadone to stabilize patients, into the high 100’s, 200’s, or more.
We saw the same trend in the 2010’s with buprenorphine doses, with some experts saying patients didn’t need over 16mg per day. Incredibly, several states (Tennessee and Virginia) passed legislation limiting patient doses to 16mg per day. Now we have study data showing that doses of 24mg and higher are associated with better treatment retention.
Studies of treatment retention could be confounded if adequate doses weren’t used.
Predictably, lower cost shows better retention in treatment. I guess I don’t need to explain that one.
Stopping methadone suddenly may feel worse to patients than stopping buprenorphine suddenly. I hear patients’ descriptions of both, and they seem to describe far worse withdrawal symptoms from methadone. Also, I suspect but cannot prove that it is easier to buy buprenorphine products on the street than it is to buy methadone. If a patient decides they want to leave treatment, for whatever reason, it may be easier to do if the patient is dosing on buprenorphine rather than methadone.
During the height of COVID, we saw better treatment retention with increased take homes. That was the reason SAMHSA changed the required time in treatment, to allow take home doses much more quickly. Not all OTPs are taking advantage of this loosening of take-home dose requirements. As I’ve blogged about in the past, medical providers should be looking closely at patients for earlier take homes.
I suspect there are factors we can’t easily quantify which influence treatment retention, like the atmosphere of the treatment program. Friendly, smiling faces are more likely to make patients feel welcome. Patients who feel accurate empathy from OTP staff – at all levels – are more likely to continue treatment. Patients who form good relationships with their counselors and medical providers are more likely to remain engaged in treatment.
Many of these factors can be changed with little effort and can have profound impact on treatment retention and survival. And maybe it’s time to recommend methadone with more vigor.
- Scholl et al., Drug and opioid-involved overdose deaths—United States, 2013–2017. MMWR Morb Mortal Wkly Rep 2019; 67 (5152):1419
- Sordo et al., “Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies, British Medical Journal,” 2017;357:1550
- Santo et al., “Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence,” JAMA Psychiatry, 2021 June 2;78(9):1-15.
- Chan et al., “Retention Strategies for Medications for Opioid Use Disorder in Adults: A Rapid Evidence Review,” Journal of Addiction Medicine, 2020 Sep 17;15(1):74–84.
- JAMA. 2024;332(21):1822-1831. doi:10.1001/jama.2024.16954
- Klimas, J., Hamilton, MA., Gorfinkel, L. et al. Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials. Syst Rev 10, 216 (2021). https://doi.org/10.1186/s13643-021-01764-9








